Education
About Us
Working with TipRanks
Follow Us
Sanofi India Limited (IN:SANOFI)
:SANOFI
SANOFI Stock Chart & Stats
₹4142.75
₹54.40(0.91%)
At close: 4:00 PM EST
₹4142.75
₹54.40(0.91%)
Day’s Range― - ―
52-Week Range₹3,500.00 - ₹6,717.50
Previous CloseN/A
Volume15.46K
Average Volume (3M)3.77K
Market Cap
₹80.66B
Enterprise Value₹77.94B
Total Cash (Recent Filing)₹3.13B
Total Debt (Recent Filing)₹209.00M
Price to Earnings (P/E)38.1
Beta0.88
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)26.80
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)170.47
Revenue Forecast (FY)₹19.55B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low leverage provides durable financial flexibility and resilience. It lowers bankruptcy and refinancing risk, supports sustained investment in product sales and distribution, and enables consistent shareholder returns or opportunistic M&A without stressing cash flows over the next 2–6 months.
Strong Free Cash Flow GenerationHigh, reliable free cash flow and tight FCF-to-income conversion indicate strong earnings quality and internal funding for capex, marketing, or dividends. The large 2025 FCF gain strengthens the company's ability to sustain operations and shareholder distributions through cyclical pressures.
High Operating Profitability And ROESustained double-digit EBIT margins and very strong ROE reflect competitive positioning, pricing power, and operational efficiency. These durable profitability metrics support internal reinvestment and returns, and indicate the business generates high returns on its equity base over time.
Bears Say
Revenue Decline And Choppy GrowthA weakening top-line trend reduces scale benefits and can impair long-run R&D, marketing, and channel investments. Continued revenue softness risks market-share loss, constrains margin leverage, and may force cost or portfolio actions that affect durable growth prospects.
Material Gross Margin CompressionA sustained fall in gross margin materially erodes core earnings power and limits the company's ability to fund SG&A and innovation. If structural (pricing pressure, cost inflation or mix shift), this weakens long-term margin sustainability and reduces operating leverage.
Decline In Equity May Distort ROE And Signal Balance-sheet ShiftsFalling equity can artificially boost ROE and may reflect outsized distributions, buybacks, or other balance-sheet moves. This reduces the capital buffer against shocks and raises questions about sustainability of returns and the quality of reported profitability over the medium term.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3500.00 and its highest was ₹6717.50 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹80.66B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Apr 28, 2026 which is in 43 days.
How were Sanofi India Limited’s earnings last quarter?
Sanofi India Limited released its earnings results on Feb 25, 2026. The company reported ₹26.8 earnings per share for the quarter, missing the consensus estimate of ₹45.05 by -₹18.25.
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹75 which represents an annual dividend yield of 4.73%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Sanofi India Limited reported an EPS of ₹26.8 in its last earnings report, missing expectations of ₹45.05. Following the earnings report the stock price went up 1.5%.
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―